World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
59505
World Ranking
6384
National Ranking
3402

Hyman B. Muss publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hyman B. Muss sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 756 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hyman B. Muss D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hyman B. Muss sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hyman B. Muss is affiliated with the University of North Carolina at Chapel Hill in the United States. Their research primarily focuses on medicine, with considerable work in oncology, pulmonary and respiratory medicine, physiology, geriatrics and gerontology, and cancer research. Over their career, they have contributed extensively to the study of cancer and aging, with particular attention to cancer survivorship and care, frailty in older adults, nutrition and health in aging, cancer treatment and pharmacology, breast cancer treatment studies, cancer-related cognitive impairment studies, and health systems including economic evaluations and quality of life.

Their recent publications demonstrate a focus on aging and cancer treatment outcomes. Notable papers include:

  • Older adult participation in cancer clinical trials: A systematic review of barriers and interventions, 2020, CA A Cancer Journal for Clinicians
  • Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer, 2021, Journal of Clinical Oncology
  • Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials, 2023, The Lancet
  • p16 a biomarker of aging and tolerance for cancer therapy, 2020, Translational Cancer Research
  • Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty, 2020, Cancer

They frequently publish in a range of venues, including:

  • UNC Libraries
  • Journal of Clinical Oncology
  • The Oncologist
  • Journal of Geriatric Oncology
  • Cancer

Muss collaborates regularly with several other researchers. Frequent coauthors include Allison M. Deal, Kirsten A. Nyrop, Grant R. Williams, Lisa A. Carey, and Harvey Jay Cohen.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

    Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

    Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert

  • c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer

    Hyman B. Muss;Ann D. Thor;Donald A. Berry;Timothy Kute

  • Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

    Kevin S. Hughes;Lauren A. Schnaper;Jennifer R. Bellon;Constance T. Cirrincione

  • Cellular senescence promotes adverse effects of chemotherapy and cancer relapse

    Marco Demaria;Marco Demaria;Monique N. O'Leary;Jianhui Chang;Lijian Shao

  • Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Marcus E. Randall;Virginia L. Filiaci;Hyman Muss;Nick M. Spirtos

  • Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

    Donald A. Berry;Constance Cirrincione;I. Craig Henderson;Marc L. Citron

  • Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer

    Daniel R. Budman;Donald A. Berry;Constance T. Cirrincione;I. Craig Henderson

  • Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

    Andrew D. Seidman;Donald Berry;Constance Cirrincione;Lyndsay Harris

  • Racial Differences in Survival From Breast Cancer: Results of the National Cancer Institute Black/White Cancer Survival Study

    J. William Eley;Holly A. Hill;Vivien W. Chen;Donald F. Austin

  • erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

    Ann D. Thor;Ann D. Thor;Donald A. Berry;Daniel R. Budman;Hyman B. Muss

  • Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

    James L. Khatcheressian;Patricia Hurley;Elissa Bantug;Laura J. Esserman

  • Developing a Cancer-Specific Geriatric Assessment: A Feasibility Study

    Arti Hurria;Supriya Gupta;Marjorie Zauderer;Enid L. Zuckerman

  • Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

    Paul E. Goss;James N. Ingle;Kathleen I. Pritchard;Nicholas J. Robert

  • American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting

    James L. Khatcheressian;Antonio C. Wolff;Thomas J. Smith;Eva Grunfeld

  • Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

    Hope S. Rugo;R. Bryan Rumble;Erin Macrae;Debra L. Barton

  • Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

    Hyman B. Muss;Hyman B. Muss;Donald A. Berry;Constance T. Cirrincione;Maria Theodoulou

Frequent Co-Authors

Bayard L. Powell
Bayard L. Powell Wake Forest University
Virginia J. Howard
Virginia J. Howard University of Alabama at Birmingham
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Eric P. Winer
Eric P. Winer Yale University
Brenda K. Edwards
Brenda K. Edwards National Institutes of Health
Larry Norton
Larry Norton Memorial Sloan Kettering Cancer Center
Pelayo Correa
Pelayo Correa Vanderbilt University
Harvey J. Cohen
Harvey J. Cohen Duke University
Ralph J. Coates
Ralph J. Coates Centers for Disease Control and Prevention
Robert J. Kurman
Robert J. Kurman Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine, there are alternative online degrees and pathways that can prepare you for key roles in healthcare. Many students look at programs like a health administration degree online to build expertise in managing healthcare operations, policy, and leadership. These degrees often pave the way for administrative and managerial roles in hospitals or clinics.

For those seeking advanced leadership roles, pursuing one of the cheap mha programs (Master of Healthcare Administration) is a cost-effective way to develop specialized business and healthcare skills. Similarly, for nurses aiming for top-level clinical or executive positions, exploring the cheapest dnp (Doctor of Nursing Practice) programs can offer both flexibility and affordability.

Pharmacists are also in high demand, and enrolling in an online pharmacy school cost can be a key consideration for aspiring professionals who want to obtain a PharmD without excessive student debt.

With the right online degree, you can take the next step in your healthcare career while balancing work, study, and financial priorities.

Best Scientists Citing Hyman B. Muss

Trending Scientists

Recently Published Articles